Reigate, United Kingdom

Christopher Stuart Dott


Average Co-Inventor Count = 2.4

ph-index = 2

Forward Citations = 30(Granted Patents)


Location History:

  • Reigate, GB (1999)
  • Redhill, GB (1999)

Company Filing History:


Years Active: 1999

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Christopher Stuart Dott: Innovator in Medical Treatments**

Introduction

Christopher Stuart Dott is a prominent inventor based in Reigate, GB. With a focus on advancements in medical treatments, he has made significant contributions to the field through his innovative patents. Dott's work primarily revolves around the improvement of therapies for postoperative conditions.

Latest Patents

Dott holds two notable patents, both pertaining to the treatment of nausea and vomiting, which are common postoperative complications. His latest patents include:

1. **Use of granisetron for the treatment of postoperative nausea and vomiting** - This invention offers a novel approach to managing these conditions effectively.

2. **Pharmaceutical compositions containing granisetron and dexamethasone** - This patent describes a method of treatment that entails administering granisetron alongside an antiemetic corticosteroid to enhance patient care.

Career Highlights

Christopher Stuart Dott has been associated with SmithKline Beecham Corporation, a reputable company in the pharmaceutical industry. His role at the company has allowed him to focus on developing innovative solutions for patient treatments.

Collaborations

Throughout his career, Dott has collaborated with esteemed colleagues such as Gareth J. Sanger and Philip Timothy Davey. These collaborations have likely contributed to the successful development and patenting of his medical innovations.

Conclusion

In conclusion, Christopher Stuart Dott has established himself as a key figure in medical innovation, particularly in treating postoperative nausea and vomiting. His contributions through patented inventions reflect his commitment to enhancing patient care and advancing pharmaceutical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…